TrialPath
Asthma · Chicago

Asthma clinical trials in Chicago

8 recruiting asthma studies within range of Chicago. Click any trial for full eligibility criteria and contact info.

Post-Vent, the Sequelae: Personalized Prognostic Modeling for Consequences of Neonatal Intermittent Hypoxemia in Preterm Infants at Pre-School Age

NCT05336890 · Premature Birth, Asthma in Children, Sleep-Disordered Breathing
Recruiting

Despite improved survival of extremely premature infants in recent decades, neonatal intensive care unit (NICU) graduates are diagnosed with asthma, sleep disordered breathing (SDB) in childhood, and neurodevelopmental impairments (NDI) at significant rates, disproportionate to their term peers. Early detection and intervention are critical to mitigate the impact of these impairments. Mechanisms leading from premature birth to these undesirable outcomes remain unclear, and accurate prognostic measures are lacking. This study wants to learn if these problems are related to certain patterns of breathing that babies had while they were in the NICU.

Phase—
TypeObservational
Age30 Weeks – 83 Months
WhereChicago, Illinois, United States
SponsorAnn & Robert H Lurie Children's Hospital of Chicago
▾Tap for details
Apply

A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

NCT07532265 · Severe Asthma
Recruiting

A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereLancaster, California, United States + 13 more
SponsorKinaset Therapeutics Inc
▾Tap for details

A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice

NCT07556159 · Asthma
Recruiting

The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and both disease-specific and generic health-related quality of life. The study consists of two parts: a cross-sectional study, and a prospective follow-up evaluate changes in disease trajectories in participants with asthma.

Phase—
TypeObservational
Age6 Years
WhereBessemer, Alabama, United States + 82 more
SponsorSanofi
▾Tap for details
Apply

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404 · Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children
Recruiting

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

Phase—
TypeObservational
Age0 Years – 20 Years
WherePhoenix, Arizona, United States + 51 more
SponsorDuke University
▾Tap for details
Apply

A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma

NCT07869043 · Asthma
Recruiting

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected. The study is seeking participants who: * Have a history of severe asthma for at least 12 months * Have had at least 2 asthma attacks (also known as exacerbations) within the last 12 months All participants will be given shots of study medicine or a placebo at the study clinic. Tilrekimig or the placebo will be given about every 4 weeks during the study. The study will compare the experiences of people receiving tilrekimig to those people who receive the placebo. This will help determine if tilrekimig is safe and effective.

PhasePhase 3
TypeInterventional
Age12 Years – 80 Years
WhereRiver Forest, Illinois, United States + 11 more
SponsorPfizer
▾Tap for details
Apply

Registry of Asthma Characterization and Recruitment 3 (RACR3)

NCT05272241 · Asthma
Recruiting

This is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Childhood Asthma in Urban Settings (CAUSE) studies.

Phase—
TypeObservational
AgeAny
WhereAurora, Colorado, United States + 6 more
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
▾Tap for details

Protocol CAUSE-03 / CHEETAH

NCT06136091 · Asthma
Recruiting

This is a one-year longitudinal, observational study of 250 urban children and adolescents with asthma and 60 without asthma, ages 6-17 years old. Participants with asthma will require daily controller therapy with inhaled corticosteroids ICS (at least Step 2 therapy). Those without asthma cannot have used asthma medications in the year prior to enrollment and cannot demonstrate bronchodilator reversibility at baseline. Phenotypic characteristics will be established at baseline, and the participants will be seen at scheduled visits over 12 months. Each participant will be asked to monitor and self-report cold symptoms and will be asked to complete up to three cold visits

Phase—
TypeObservational
Age6 Years – 17 Years
WhereAurora, Colorado, United States + 7 more
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
▾Tap for details

Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study

NCT05667701 · Wheezing, Asthma in Children
Recruiting

The goal of this clinical trial is to compare soy isoflavones to placebo in children who at risk of asthma and have a genetic variation which results in them making more of a pro-inflammatory protein, plasminogen activator inhibitor-1. The main questions this trail seeks to answer is: will soy isoflavones decrease the proportion of infants with aT2 high endotype at the end of treatment, and secondarily decrease the number of wheezing episodes in these children when given in the first year of life. Participants will be asked to ingest soy isoflavone or placebo twice daily mixed into a liquid or puree vehicle for 7 months from randomization. There will be 3 mandatory in-person visits, and 6 virtual visits in the first year. There will also be 11 monthly questionnaires and 1 in person visit in the observation year. Participants will have 4 nasal swabs, 3 blood draws, and also provide 4 stool samples over the course of the study.

PhasePhase 2
TypeInterventional
Age2 Months – 12 Months
WhereChicago, Illinois, United States + 1 more
SponsorRajesh Kumar
▾Tap for details
Apply